Abstract
The purpose of the study is to experimentally substantiate the immunobiological properties, protective efficacy, duration of action, and safety of a new subunit vaccine against brucellosis in small ruminants. The vaccine was developed based on a recombinant outer membrane protein of Brucella melitensis, and its efficacy was evaluated using a BALB/c mouse model. The recombinant method provides the highest yield of antigenic protein (145±18 milligrams per litre), preparation stability for up to 12 months, and a production time of 14±3 days. Expression of the target gene is confirmed using quantitative reverse transcription polymerase chain reaction, showing a 12.6-fold increase in messenger RNA levels. Specificity of the obtained antigen is demonstrated using immunoblotting (intensity of 1680±140 arbitrary units compared with 280±60 units in the control) and mass spectrometry with 78.3 per cent coverage of the amino acid sequence. Immunisation induces an increase in IgG (up to 1:5120), a rise in the proportion of helper-type T-lymphocytes to 32 per cent, and an interferon-gamma (IFN-γ) concentration of 450 picograms per millilitre. Following infection, survival in the experimental group is 95 per cent, whereas the group receiving the standard live vaccine Rev.1 shows 75 per cent survival; histological changes in liver and spleen tissues are minimal. At 180 days post-immunisation, the IgG remained at 1:1920, IFN-γ concentration measured 220 picograms per millilitre, and the protective effect was maintained in 90 per cent of vaccinated animals.

This publication has 29 references indexed in Scilit: